Abstract PS1-11-01: Impact of prior CDK 4/6 inhibitor treatment on the efficacy of everolimus and exemestane or fulvestrant in hormone receptor positive HER 2 negative (HR+/HER2-) metastatic breast cancer (MBC): a restrospective analysis of 144 patients